TickerTalks
Browse all tickers →
TickerTalks›$GLUE
GLGLUE

Monte Rosa Therapeutics, Inc.

$GLUE·$1.4B·Biotechnology·Healthcare
——
Mentions · last 7 days
2026-07-25: 2 posts2026-07-26: 5 posts2026-07-27: 8 posts2026-07-28: 5 posts2026-07-29: 3 posts2026-07-30: 5 posts2026-07-31: 47 posts76
X counts updated 3h ago
GLGLUE
$GLUEMonte Rosa Therapeutics, Inc.
——76 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $GLUE.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-21.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-345%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
32.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-41.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
95.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.45$-0.28-60.7%
Q4 2025Mar 17, 2026$-0.54$-0.35-53.6%
Q3 2025Nov 6, 2025$-0.33$-0.37+9.9%
Q2 2025Aug 7, 2025$-0.15$-0.38+60.2%
Next earningsThu, Aug 6·consensus EPS $-0.37

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.2M-95.0%51.8%-1188%$-0.68$-39.2M
Q4 FY25$2.8M-95.4%100%-1788%$-0.70$-43.8M
Q3 FY25$12.8M+38.5%100%-258%$-0.33$99.8M
Q2 FY25$23.2M+394.0%100%-67.1%$-0.15$-36.4M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$44.5M$10.7M – $98.2M-$1.66-$2.52 – -$0.325
FY27$58.2M$19.1M – $136.5M-$1.84-$3.20 – $0.625
FY28$16.6M$3.8M – $47.8M-$2.33-$3.01 – -$1.555
FY29$84.8M$19.6M – $245.0M-$2.25-$7.77 – -$0.002
FY30$124.4M$28.7M – $359.4M-$1.96-$6.79 – -$0.002

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$CAPR$IBRX$REGN$HALO$AURA$ALLO$MRNA$REPL
Voices on X · top 11 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport